AVM
VERV

Arch Venture Management’s Verve Therapeutics VERV Stock Holding History

Arch Venture Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,008,809
Closed -$22.6M – 11
2025
Q2 		$22.6M Hold
2,008,809
– – 7.54% 5
2025
Q1 		$9.12M Hold
2,008,809
– – 4.42% 5
2024
Q4 		$11.3M Hold
2,008,809
– – 4.92% 4
2024
Q3 		$9.72M Hold
2,008,809
– – 3.73% 5
2024
Q2 		$9.8M Hold
2,008,809
– – 3.69% 4
2024
Q1 		$26.7M Hold
2,008,809
– – 33.23% 1
2023
Q4 		$28M Hold
2,008,809
– – 17.13% 2
2023
Q3 		$26.6M Hold
2,008,809
– – 17.3% 2
2023
Q2 		$37.7M Hold
2,008,809
– – 23.26% 2
2023
Q1 		$29M Hold
2,008,809
– – 13.98% 4
2022
Q4 		$38.9M Hold
2,008,809
– – 9.96% 5
2022
Q3 		$69M Sell
2,008,809
-500,000
-20% -$16M 8.95% 5
2022
Q2 		$38.3M Hold
2,508,809
– – 4.67% 5
2022
Q1 		$57.3M Hold
2,508,809
– – 8.18% 4
2021
Q4 		$92.5M Buy
+2,508,809
New +$105M 9.79% 4

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Arch Venture Management's VERV Position: Q3 2025 in Review

Arch Venture Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 2,008,809 shares — an estimated $22.6M sold.

Arch Venture Management first reported a position in VERV in Q4 2021 and held it in 15 quarters. The position peaked at $92.5M in Q4 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Arch Venture Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Arch Venture Management sold 2,008,809 Verve Therapeutics shares in Q3 2025, an estimated $22.6M.
  • Arch Venture Management first reported a position in Verve Therapeutics in Q4 2021 and held it in 15 quarters.
  • Arch Venture Management's Verve Therapeutics position peaked at $92.5M in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Arch Venture Management's 13F filing for Q3 2025, filed 14 Nov 2025.